Department of Urology, Tulane University Health Sciences Center, New Orleans, LA, USA.
Prostate Cancer Prostatic Dis. 2010 Jun;13(2):195-201. doi: 10.1038/pcan.2009.55. Epub 2009 Dec 22.
We have identified a novel function for a member of the transient receptor potential (TRP) protein super-family, TRPM2, in prostate cancer cell proliferation. TRPM2 encodes a non-selective cation-permeable ion channel. We found that selectively knocking down TRPM2 with the small interfering RNA technique inhibited the growth of prostate cancer cells but not of non-cancerous cells. The subcellular localization of this protein is also remarkably different between cancerous and non-cancerous cells. In BPH-1 (benign), TRPM2 protein is homogenously located near the plasma membrane and in the cytoplasm, whereas in the cancerous cells (PC-3 and DU-145), a significant amount of the TRPM2 protein is located in the nuclei in a clustered pattern. Furthermore, we have found that TRPM2 inhibited nuclear ADP-ribosylation in prostate cancer cells. However, TRPM2 knockdown-induced inhibition of proliferation is independent of the activity of poly(ADP-ribose) polymerases. We conclude that TRPM2 is essential for prostate cancer cell proliferation and may be a potential target for the selective treatment of prostate cancer.
我们发现瞬时受体电位(TRP)蛋白家族的一个新成员 TRPM2 在前列腺癌细胞增殖中具有新的功能。TRPM2 编码一种非选择性阳离子渗透性离子通道。我们发现,用小干扰 RNA 技术选择性地敲低 TRPM2 不仅抑制了前列腺癌细胞的生长,也抑制了非癌细胞的生长。这种蛋白的亚细胞定位在癌细胞和非癌细胞之间也有显著差异。在 BPH-1(良性)中,TRPM2 蛋白均匀地位于靠近质膜和细胞质的位置,而在癌细胞(PC-3 和 DU-145)中,大量的 TRPM2 蛋白以聚集的模式位于核内。此外,我们发现 TRPM2 抑制了前列腺癌细胞的核 ADP-核糖基化。然而,TRPM2 敲低诱导的增殖抑制与聚(ADP-核糖)聚合酶的活性无关。我们的结论是,TRPM2 是前列腺癌细胞增殖所必需的,可能是前列腺癌选择性治疗的潜在靶点。